N-2-pyridinyl-β-Alanine,ethylester is a key intermediate in the field of medicine, such as dabigatran ester, a new direct thrombin inhibitor. The drug was developed by breinger Ingelheim company in Germany. It was first listed in Germany and the UK in April 2008. It is the first new class of oral anticoagulant drug in 50 years after warfarin.